Shanghai, China

Yuncheng Zheng

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Ampsource Biopharma Shanghai Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuncheng Zheng. Retrieved from https://idiyas.com/inventor/yuncheng-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 83.3

 

 

Average Co-Inventor Count = 8.2

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations by Yuncheng Zheng: Pioneering Antibody Development

Introduction

Yuncheng Zheng, an accomplished inventor based in Shanghai, China, has significantly contributed to the field of biopharmaceuticals. With a record of holding six patents, Zheng's innovative work primarily focuses on antibody development and fusion protein technology, making strides in the treatment of various diseases.

Latest Patents

Among Zheng's latest patents is one titled "Antibody against TIM-3 and application thereof." This invention encompasses an antibody targeted at the human TIM-3, along with an antigen-binding fragment. It includes a nucleic acid molecule encoding the antibody, an expression vector for its production, and a method for generating the antibody. Additionally, it formulates a pharmaceutical composition involving the antibody, aimed at preventing and treating a range of conditions, such as tumors, infectious diseases, and autoimmune disorders.

Another significant patent by Zheng is for a "Linker peptide for constructing fusion protein." This invention details a linker peptide comprising both a flexible and a rigid peptide designed to minimize mutual steric hindrance between two fusion molecules. The flexible peptide consists of multiple flexible units, while the rigid peptide features a human chorionic gonadotropin β-subunit carboxy-terminal peptide. This innovative design enhances the stability and bioavailability of fused proteins, optimizing their therapeutic potential.

Career Highlights

Yuncheng Zheng has had impactful roles in notable companies within the biopharmaceutical sector. He has contributed his expertise to Ampsource Biopharma Shanghai Inc. and Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. His work has facilitated advancements in therapeutic treatments, making him a respected figure in his industry.

Collaborations

Zheng has collaborated with distinguished colleagues, including Qiang Li and Yuanli Li. These partnerships have fostered an environment of innovation and have played a crucial role in the progress of their collective research endeavors.

Conclusion

Yuncheng Zheng's contributions to the field of biopharmaceuticals through his innovative patents exemplify his commitment to improving healthcare solutions. His work on antibodies and fusion proteins not only showcases his inventive spirit but also highlights the potential impact of his inventions on treating various diseases. As the landscape of medical technology evolves, Zheng remains a prominent figure to watch in the realm of biopharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…